<DOC>
	<DOCNO>NCT00865969</DOCNO>
	<brief_summary>The purpose study assess efficacy safety belinostat patient relapse refractory peripheral T-cell lymphoma ( PTCL ) , fail least one prior systemic therapy .</brief_summary>
	<brief_title>Belinostat Relapsed Refractory Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description>This open-label , multicenter , single arm efficacy safety study patient relapse refractory peripheral T-cell lymphoma , fail least one prior systemic therapy . Approximately 120 patient enrol . Patients treated 1000 mg/m² belinostat administer 30-minute IV infusion day 1-5 every 3-week cycle disease progression unmanageable treatment-related toxicity . The primary study endpoint objective response rate ( ORR ) base IHP revision IWG criterion . Safety evaluate study 30 day last administration study drug . Adverse event laboratory study grade accord NCI-CTCAE v. 3.0 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : A histologically confirm diagnosis PTCL Patients must relapse refractory disease least one prior systemic anticancer regimen . Systemic anticancer therapy define chemotherapy immunotherapy administer systemically . Patients must least one site disease measurable two dimension compute tomography ( CT ) . Age ≥ 18 year . Adequate bone marrow , liver , renal function . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Negative pregnancy test woman childbearing potential . Exclusion criterion : Relapse within 100 day autologous allogeneic bone marrow transplant . Prior HDAC inhibitor therapy . Coexisting active infection medical condition likely interfere trial procedure . Severe cardiovascular disease . Clinically significant central nervous system disorder alter mental status psychiatric disorder preclude understanding informed consent process and/or completion necessary study . Active concurrent malignancy ( except adequately treat nonmelanoma skin cancer carcinoma situ cervix ) . Symptomatic untreated central nervous system ( CNS ) metastases . Pregnant breastfeed woman . Known infection HIV , hepatitis B hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Belinostat</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>PXD101</keyword>
	<keyword>PTCL</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>histone deacetylase inhibitor</keyword>
</DOC>